<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01061333</url>
  </required_header>
  <id_info>
    <org_study_id>0000-176</org_study_id>
    <secondary_id>2010_507</secondary_id>
    <nct_id>NCT01061333</nct_id>
  </id_info>
  <brief_title>Early Airway Response to Allergen in Asthmatics (MK-0000-176)</brief_title>
  <official_title>A Two-Part, Randomized, Placebo-Controlled, Crossover Trial to Evaluate the Differential Effects of Inhaled Nedocromil, Oral Montelukast, and Inhaled Mometasone on Markers of the Early Airway Response to Allergen in Asthmatics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the Early Airway Response (EAR) associated change in forced expiratory
      volume in one second (FEV1) and plasma 9α-11ß-PGF2 ('9P') after single dose pretreatment of
      nedocromil, montelukast, and mometasone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Pre-allergen challenge and 20 minutes after allergen challenge</time_frame>
    <description>Maximal percent drop in FEV1 at 20 minutes post allergen challenge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Plasma 9α-11β-PGF2 (9P) at 5 Minutes</measure>
    <time_frame>Pre-allergen challenge and 5 minutes post allergen challenge</time_frame>
    <description>Fold change over baseline of plasma 9P at 5 minutes post-allergen challenge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Plasma 9P at 20 Minutes</measure>
    <time_frame>Pre-allergen challenge and 20 minutes post allergen challenge</time_frame>
    <description>Fold change over baseline of plasma 9P at 20 minutes post-allergen challenge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Allergen-induced Changes in Urinary 9P</measure>
    <time_frame>Baseline and 2 hours post allergen challenge</time_frame>
    <description>Fold change over baseline in Urinary 9P at 2 hours post allergen challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allergen-induced Changes in Urinary Leukotriene (LT) E4</measure>
    <time_frame>Baseline and 2 hours post allergen challenge</time_frame>
    <description>Fold change over baseline in urinary LTE4 at 2 hours post-allergen challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allergen-induced Concentrations of Sputum LTC4</measure>
    <time_frame>2 hours post allergen challenge</time_frame>
    <description>Concentrations of LTC4 in sputum at 2 hours post-allergen challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allergen-induced Concentrations of Sputum LTD4</measure>
    <time_frame>2 hours post allergen challenge</time_frame>
    <description>Concentrations of LTD4 in sputum at 2 hours post-allergen challenge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allergen-induced Concentrations of Sputum LTE4</measure>
    <time_frame>2 hours post allergen challenge</time_frame>
    <description>Concentrations of LTE4 in sputum at 2 hours post-allergen challenge</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Montelukast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Montelukast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nedocromil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nedocromil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mometasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mometasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nedocromil</intervention_name>
    <description>Nedocromil 4 mg, as metered dose inhaler 1 hour prior to allergen challenge</description>
    <arm_group_label>Nedocromil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Montelukast</intervention_name>
    <description>Montelukast single 10 mg tablet administered 2 hours prior to allergen challenge</description>
    <arm_group_label>Montelukast</arm_group_label>
    <other_name>Singulair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Mometasone</intervention_name>
    <description>Mometasone furoate 400 mcg by twisthaler, administered 2 hours prior to allergen challenge</description>
    <arm_group_label>Mometasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Mometasone placebo twisthaler, Nedocromil placebo metered dose inhaler, Montelukast placebo tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of mild to moderate Asthma

          -  In good general health (except for asthma)

          -  Stable and free of respiratory infection

          -  Nonsmoker

          -  Females highly unlikely to conceive (surgically sterilized, postmenopausal, or agrees
             to use 2 acceptable methods of birth control)

        Exclusion Criteria:

          -  Nursing mother

          -  Recent or ongoing upper or lower respiratory tract infection

          -  Unable to refrain from or anticipates the use of any prescription and non-prescription
             drugs

          -  Consumes excessive amounts of alcohol or caffeine

          -  History of stroke, chronic seizures, or major neurological disorder

          -  History of cancer

          -  Received a vaccination within the past 3 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2010</study_first_submitted>
  <study_first_submitted_qc>February 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2010</study_first_posted>
  <results_first_submitted>April 26, 2012</results_first_submitted>
  <results_first_submitted_qc>April 26, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 28, 2012</results_first_posted>
  <last_update_submitted>September 3, 2015</last_update_submitted>
  <last_update_submitted_qc>September 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
    <mesh_term>Nedocromil</mesh_term>
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo-Montelukast-Nedocromil-Mometasone</title>
          <description>Over the course of four 3-day treatment regimens, participants received a single dose of each drug starting with placebo, crossover of nedocromil or montelukast, crossover of nedocromil or montelukast, ending with mometasone; with a 20-day washout between each of the four treatment periods.</description>
        </group>
        <group group_id="P2">
          <title>Placebo-Nedocromil-Montelukast-Mometasone</title>
          <description>Over the course of four 3-day treatment regimens, participants received a single dose of each drug starting with placebo, crossover of nedocromil or montelukast, crossover of nedocromil or montelukast, ending with mometasone; with a 20-day washout between each of the four treatment periods.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1: Placebo Run-in</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2: 20-day Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3: Nedocromil-Montelukast X-over</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4: 20-day Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Discontinued by Study Team</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 5: Nedocromil-Montelukast X-over</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 6: 20-day Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 7: Mometasone</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Over the course of four 3-day treatment regimens, participants received a single dose of each drug starting with placebo, nedocromil or montelukast, nedocromil or montelukast, ending with mometasone; with a 20-day washout between each of the four treatment periods.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.94" spread="7.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Maximal percent drop in FEV1 at 20 minutes post allergen challenge</description>
        <time_frame>Pre-allergen challenge and 20 minutes after allergen challenge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Nedocromil placebo metered dose inhaler, montelukast placebo tablet, mometasone placebo twisthaler</description>
          </group>
          <group group_id="O2">
            <title>Nedocromil</title>
            <description>Nedocromil 4 mg, administered by metered dose inhaler, 1 hour prior to allergen challenge</description>
          </group>
          <group group_id="O3">
            <title>Montelukast</title>
            <description>Montelukast 10 mg, administered in a single tablet, 2 hours prior to allergen challenge</description>
          </group>
          <group group_id="O4">
            <title>Mometasone</title>
            <description>Mometasone furoate 400 mcg, administered by twisthaler, 2 hours prior to allergen challenge</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Maximal percent drop in FEV1 at 20 minutes post allergen challenge</description>
          <units>Percentage drop in FEV1</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.66" spread="10.72"/>
                    <measurement group_id="O2" value="-8.44" spread="6.15"/>
                    <measurement group_id="O3" value="-9.15" spread="6.96"/>
                    <measurement group_id="O4" value="-16.17" spread="11.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-value not adjusted for simultaneous multiple comparisons</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in LS mean</param_type>
            <param_value>16.22</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.74</ci_lower_limit>
            <ci_upper_limit>21.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>p-value not adjusted for simultaneous multiple comparisons</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in LS Mean</param_type>
            <param_value>15.51</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.00</ci_lower_limit>
            <ci_upper_limit>21.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0432</p_value>
            <p_value_desc>p-value not adjusted for simultaneous multiple comparisons</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in LS Mean</param_type>
            <param_value>8.49</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.78</ci_lower_limit>
            <ci_upper_limit>15.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Plasma 9α-11β-PGF2 (9P) at 5 Minutes</title>
        <description>Fold change over baseline of plasma 9P at 5 minutes post-allergen challenge</description>
        <time_frame>Pre-allergen challenge and 5 minutes post allergen challenge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Nedocromil placebo metered dose inhaler, Montelukast placebo tablet, Mometasone placebo twisthaler</description>
          </group>
          <group group_id="O2">
            <title>Nedocromil</title>
            <description>Nedocromil 4 mg, administered by metered dose inhaler, 1 hour prior to allergen challenge</description>
          </group>
          <group group_id="O3">
            <title>Montelukast</title>
            <description>Montelukast 10 mg, administered in a single tablet, 2 hours prior to allergen challenge</description>
          </group>
          <group group_id="O4">
            <title>Mometasone</title>
            <description>Mometasone furoate 400 mcg, administered by twisthaler, 2 hours prior to allergen challenge</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma 9α-11β-PGF2 (9P) at 5 Minutes</title>
          <description>Fold change over baseline of plasma 9P at 5 minutes post-allergen challenge</description>
          <units>Fold change over baseline</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.21"/>
                    <measurement group_id="O2" value="0.97" spread="0.17"/>
                    <measurement group_id="O3" value="1.08" spread="0.44"/>
                    <measurement group_id="O4" value="1.00" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0430</p_value>
            <p_value_desc>p-Value not adjusted for simultaneous multiple comparisons</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>concentrations evaluated at log scale</method_desc>
            <param_type>Geom. Mean Ratio of fold over baseline</param_type>
            <param_value>1.27</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>1.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0100</p_value>
            <p_value_desc>p-Value not adjusted for simultaneous multiple comparisons</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>concentrations evaluated at log scale</method_desc>
            <param_type>Geom. Mean Ratio of fold over baseline</param_type>
            <param_value>1.41</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.15</ci_lower_limit>
            <ci_upper_limit>1.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0860</p_value>
            <p_value_desc>p-Value not adjusted for simultaneous multiple comparisons</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>concentrations evaluated at log scale</method_desc>
            <param_type>Geom. Mean Ratio of fold over baseline</param_type>
            <param_value>1.30</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Plasma 9P at 20 Minutes</title>
        <description>Fold change over baseline of plasma 9P at 20 minutes post-allergen challenge</description>
        <time_frame>Pre-allergen challenge and 20 minutes post allergen challenge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Nedocromil placebo metered dose inhaler, montelukast placebo tablet, mometasone placebo twisthaler</description>
          </group>
          <group group_id="O2">
            <title>Nedocromil</title>
            <description>Nedocromil 4 mg, administered by metered dose inhaler, 1 hour prior to allergen challenge</description>
          </group>
          <group group_id="O3">
            <title>Montelukast</title>
            <description>Montelukast 10 mg, administered in a single tablet, 2 hours prior to allergen challenge</description>
          </group>
          <group group_id="O4">
            <title>Mometasone</title>
            <description>Mometasone furoate 400 mcg, administered by twisthaler, 2 hours prior to allergen challenge</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma 9P at 20 Minutes</title>
          <description>Fold change over baseline of plasma 9P at 20 minutes post-allergen challenge</description>
          <units>Fold change over baseline</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread="0.31"/>
                    <measurement group_id="O2" value="0.72" spread="0.25"/>
                    <measurement group_id="O3" value="0.72" spread="0.21"/>
                    <measurement group_id="O4" value="1.06" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-Value not adjusted for simultaneous multiple comparisons</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>concentrations evaluated at log scale</method_desc>
            <param_type>Geom. Mean Ratio of fold over baseline</param_type>
            <param_value>0.59</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>0.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-Value not adjusted for simultaneous multiple comparisons</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>concentrations evaluated at log scale</method_desc>
            <param_type>Geom. Mean Ratio of fold over baseline</param_type>
            <param_value>0.59</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>0.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2679</p_value>
            <p_value_desc>p-Value not adjusted for simultaneous multiple comparisons</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>concentrations evaluated at log scale</method_desc>
            <param_type>Geom. Mean Ratio of fold over baseline</param_type>
            <param_value>0.87</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Allergen-induced Changes in Urinary 9P</title>
        <description>Fold change over baseline in Urinary 9P at 2 hours post allergen challenge</description>
        <time_frame>Baseline and 2 hours post allergen challenge</time_frame>
        <population>Only participants with baseline values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Nedocromil placebo metered dose inhaler, montelukast placebo tablet, mometasone placebo twisthaler</description>
          </group>
          <group group_id="O2">
            <title>Nedocromil</title>
            <description>Nedocromil 4 mg, administered by metered dose inhaler, 1 hour prior to allergen challenge</description>
          </group>
          <group group_id="O3">
            <title>Montelukast</title>
            <description>Montelukast 10 mg, administered in a single tablet, 2 hours prior to allergen challenge</description>
          </group>
          <group group_id="O4">
            <title>Mometasone</title>
            <description>Mometasone furoate 400 mcg, administered by twisthaler, 2 hours prior to allergen challenge</description>
          </group>
        </group_list>
        <measure>
          <title>Allergen-induced Changes in Urinary 9P</title>
          <description>Fold change over baseline in Urinary 9P at 2 hours post allergen challenge</description>
          <population>Only participants with baseline values were analyzed</population>
          <units>Fold change over baseline</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="2.43"/>
                    <measurement group_id="O2" value="1.39" spread="2.54"/>
                    <measurement group_id="O3" value="1.45" spread="4.22"/>
                    <measurement group_id="O4" value="1.40" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7622</p_value>
            <p_value_desc>p-Value not adjusted for simultaneous multiple comparisons</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>concentrations evaluated at log scale</method_desc>
            <param_type>Geom. Mean Ratio of fold over baseline</param_type>
            <param_value>0.90</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8468</p_value>
            <p_value_desc>p-Value not adjusted for simultaneous multiple comparisons</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>concentrations evaluated on log scale</method_desc>
            <param_type>Geom. Mean Ratio of fold over baseline</param_type>
            <param_value>0.94</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>1.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6140</p_value>
            <p_value_desc>p-Value not adjusted for simultaneous multiple comparisons</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>concentrations evaluated at log scale</method_desc>
            <param_type>Geom. Mean Ratio of fold over baseline</param_type>
            <param_value>0.91</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Allergen-induced Changes in Urinary Leukotriene (LT) E4</title>
        <description>Fold change over baseline in urinary LTE4 at 2 hours post-allergen challenge</description>
        <time_frame>Baseline and 2 hours post allergen challenge</time_frame>
        <population>Only participants with baseline values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Nedocromil placebo metered dose inhaler, montelukast placebo tablet, mometasone placebo twisthaler</description>
          </group>
          <group group_id="O2">
            <title>Nedocromil</title>
            <description>Nedocromil 4 mg, administered by metered dose inhaler, 1 hour prior to allergen challenge</description>
          </group>
          <group group_id="O3">
            <title>Montelukast</title>
            <description>Montelukast 10 mg, administered in a single tablet, 2 hours prior to allergen challenge</description>
          </group>
          <group group_id="O4">
            <title>Mometasone</title>
            <description>Mometasone furoate 400 mcg, administered by twisthaler, 2 hours prior to allergen challenge</description>
          </group>
        </group_list>
        <measure>
          <title>Allergen-induced Changes in Urinary Leukotriene (LT) E4</title>
          <description>Fold change over baseline in urinary LTE4 at 2 hours post-allergen challenge</description>
          <population>Only participants with baseline values were analyzed</population>
          <units>Fold change over baseline</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="1.09"/>
                    <measurement group_id="O2" value="1.19" spread="1.31"/>
                    <measurement group_id="O3" value="1.40" spread="1.52"/>
                    <measurement group_id="O4" value="1.62" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>p-Value not adjusted for simultaneous multiple comparisons</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>concentrations evaluated at log scale</method_desc>
            <param_type>Geom. Mean Ratio of fold over baseline</param_type>
            <param_value>0.67</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>0.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0291</p_value>
            <p_value_desc>p-Value not adjusted for simultaneous multiple comparisons</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>concentrations evaluated at log scale</method_desc>
            <param_type>Geom. Mean Ratio of fold over baseline</param_type>
            <param_value>0.79</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3738</p_value>
            <p_value_desc>p-Value not adjusted for simultaneous multiple comparisons</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>concentrations evaluated at log scale</method_desc>
            <param_type>Geom. Mean Ratio of fold over baseline</param_type>
            <param_value>0.92</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Allergen-induced Concentrations of Sputum LTC4</title>
        <description>Concentrations of LTC4 in sputum at 2 hours post-allergen challenge</description>
        <time_frame>2 hours post allergen challenge</time_frame>
        <population>Pre-imputation status. Missing data points were excluded and values below the lower limit of quantification (LLOQ) were included in the analysis with an assigned value of assay LLOQ.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Nedocromil placebo metered dose inhaler, montelukast placebo tablet, mometasone placebo twisthaler</description>
          </group>
          <group group_id="O2">
            <title>Nedocromil</title>
            <description>Nedocromil 4 mg, administered by metered dose inhaler, 1 hour prior to allergen challenge</description>
          </group>
          <group group_id="O3">
            <title>Montelukast</title>
            <description>Montelukast 10 mg, administered in a single tablet, 2 hours prior to allergen challenge</description>
          </group>
          <group group_id="O4">
            <title>Mometasone</title>
            <description>Mometasone furoate 400 mcg, administered by twisthaler, 2 hours prior to allergen challenge</description>
          </group>
        </group_list>
        <measure>
          <title>Allergen-induced Concentrations of Sputum LTC4</title>
          <description>Concentrations of LTC4 in sputum at 2 hours post-allergen challenge</description>
          <population>Pre-imputation status. Missing data points were excluded and values below the lower limit of quantification (LLOQ) were included in the analysis with an assigned value of assay LLOQ.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.63" spread="8.22"/>
                    <measurement group_id="O2" value="14.02" spread="12.53"/>
                    <measurement group_id="O3" value="13.76" spread="5.45"/>
                    <measurement group_id="O4" value="12.14" spread="6.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7501</p_value>
            <p_value_desc>p-Value not adjusted for simultaneous multiple comparisons</p_value_desc>
            <method>ANOVA</method>
            <method_desc>concentrations evaluated at log scale</method_desc>
            <param_type>Geom. mean of fold change over Placebo</param_type>
            <param_value>1.03</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9410</p_value>
            <p_value_desc>p-Value not adjusted for simultaneous multiple comparisons</p_value_desc>
            <method>ANOVA</method>
            <method_desc>concentrations evaluated at log scale</method_desc>
            <param_type>Geom. mean of fold change over Placebo</param_type>
            <param_value>1.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1165</p_value>
            <p_value_desc>p-Value not adjusted for simultaneous multiple comparisons</p_value_desc>
            <method>ANOVA</method>
            <method_desc>concentrations evaluated at log scale</method_desc>
            <param_type>Geom. mean of fold change over Placebo</param_type>
            <param_value>0.89</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Allergen-induced Concentrations of Sputum LTD4</title>
        <description>Concentrations of LTD4 in sputum at 2 hours post-allergen challenge</description>
        <time_frame>2 hours post allergen challenge</time_frame>
        <population>Pre-imputation status. Missing data points were excluded and values below the lower limit of quantification (LLOQ) were included in the analysis with an assigned value of assay LLOQ.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Nedocromil placebo metered dose inhaler, montelukast placebo tablet, mometasone placebo twisthaler</description>
          </group>
          <group group_id="O2">
            <title>Nedocromil</title>
            <description>Nedocromil 4 mg, administered by metered dose inhaler, 1 hour prior to allergen challenge</description>
          </group>
          <group group_id="O3">
            <title>Montelukast</title>
            <description>Montelukast 10 mg, administered in a single tablet, 2 hours prior to allergen challenge</description>
          </group>
          <group group_id="O4">
            <title>Mometasone</title>
            <description>Mometasone furoate 400 mcg, administered by twisthaler, 2 hours prior to allergen challenge</description>
          </group>
        </group_list>
        <measure>
          <title>Allergen-induced Concentrations of Sputum LTD4</title>
          <description>Concentrations of LTD4 in sputum at 2 hours post-allergen challenge</description>
          <population>Pre-imputation status. Missing data points were excluded and values below the lower limit of quantification (LLOQ) were included in the analysis with an assigned value of assay LLOQ.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.48" spread="15.20"/>
                    <measurement group_id="O2" value="18.04" spread="31.13"/>
                    <measurement group_id="O3" value="18.52" spread="9.22"/>
                    <measurement group_id="O4" value="17.37" spread="36.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8616</p_value>
            <p_value_desc>p-Value not adjusted for simultaneous multiple comparisons</p_value_desc>
            <method>ANOVA</method>
            <method_desc>concentrations evaluated at log scale</method_desc>
            <param_type>Geom. mean of fold change over Placebo</param_type>
            <param_value>1.03</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7512</p_value>
            <p_value_desc>p-Value not adjusted for simultaneous multiple comparisons</p_value_desc>
            <method>ANOVA</method>
            <method_desc>concentrations evaluated at log scale</method_desc>
            <param_type>Geom. mean of fold change over Placebo</param_type>
            <param_value>1.06</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9723</p_value>
            <p_value_desc>p-Value not adjusted for simultaneous multiple comparisons</p_value_desc>
            <method>ANOVA</method>
            <method_desc>concentrations evaluated at log scale</method_desc>
            <param_type>Geom. mean of fold change over Placebo</param_type>
            <param_value>0.99</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Allergen-induced Concentrations of Sputum LTE4</title>
        <description>Concentrations of LTE4 in sputum at 2 hours post-allergen challenge</description>
        <time_frame>2 hours post allergen challenge</time_frame>
        <population>Pre-imputation status. Missing data points were excluded and values below the lower limit of quantification (LLOQ) were included in the analysis with an assigned value of assay LLOQ.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Nedocromil placebo metered dose inhaler, montelukast placebo tablet, mometasone placebo twisthaler</description>
          </group>
          <group group_id="O2">
            <title>Nedocromil</title>
            <description>Nedocromil 4 mg, administered by metered dose inhaler, 1 hour prior to allergen challenge</description>
          </group>
          <group group_id="O3">
            <title>Montelukast</title>
            <description>Montelukast 10 mg, administered in a single tablet, 2 hours prior to allergen challenge</description>
          </group>
          <group group_id="O4">
            <title>Mometasone</title>
            <description>Mometasone furoate 400 mcg, administered by twisthaler, 2 hours prior to allergen challenge</description>
          </group>
        </group_list>
        <measure>
          <title>Allergen-induced Concentrations of Sputum LTE4</title>
          <description>Concentrations of LTE4 in sputum at 2 hours post-allergen challenge</description>
          <population>Pre-imputation status. Missing data points were excluded and values below the lower limit of quantification (LLOQ) were included in the analysis with an assigned value of assay LLOQ.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.5" spread="129.0"/>
                    <measurement group_id="O2" value="149.8" spread="178.7"/>
                    <measurement group_id="O3" value="181.3" spread="227.6"/>
                    <measurement group_id="O4" value="140.3" spread="215.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1983</p_value>
            <p_value_desc>p-Value not adjusted for simultaneous multiple comparisons</p_value_desc>
            <method>ANOVA</method>
            <method_desc>concentrations evaluated at log scale</method_desc>
            <param_type>Geom. mean of fold change over Placebo</param_type>
            <param_value>1.30</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0872</p_value>
            <p_value_desc>p-Value not adjusted for simultaneous multiple comparisons</p_value_desc>
            <method>ANOVA</method>
            <method_desc>concentrations evaluated at log scale</method_desc>
            <param_type>Geom. mean of fold change over Placebo</param_type>
            <param_value>1.57</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>2.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2499</p_value>
            <p_value_desc>p-Value not adjusted for simultaneous multiple comparisons</p_value_desc>
            <method>ANOVA</method>
            <method_desc>concentrations evaluated at log scale</method_desc>
            <param_type>Geom. mean of fold change over Placebo</param_type>
            <param_value>1.22</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Nedocromil placebo metered dose inhaler, montelukast placebo tablet, mometasone placebo twisthaler</description>
        </group>
        <group group_id="E2">
          <title>Nedocromil</title>
          <description>Nedocromil 4 mg, administered by metered dose inhaler, 1 hour prior to allergen challenge</description>
        </group>
        <group group_id="E3">
          <title>Montelukast</title>
          <description>Montelukast 10 mg, administered in a single tablet, 2 hours prior to allergen challenge</description>
        </group>
        <group group_id="E4">
          <title>Mometasone</title>
          <description>Mometasone furoate 400 mcg, administered by twisthaler, 2 hours prior to allergen challenge</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint Sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>For multicenter studies, subsequent to the multicenter publication, an investigator and colleagues may publish their data independently. Limitations of single site observations should always be described in such a manuscript. The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this study 60 days prior to submission. Any information identified by the SPONSOR as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

